CMAJ - April 1, 1997 / Table 3: Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada

Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada

Table 3: Estimated cost-effectiveness ratios for long-term (15-year) simvastatin treatment in Canada according to 3 premises of clinical benefit

Cost per YLG
ą 20%,‡ $

Premise* Cost per YLG,† $ -20% +20%

A (one-time benefit) 29 888 22 695 37 081

B (semicontinuous benefit) 9 867 7 044 12 690

C (continuous benefit) 6 108 4 030 8 186

*See Methods for descriptions of premises.
†YLG = year of life gained.
‡Costs are varied by 20% for sensitivity analysis.

[Return to text]

| CMAJ April 1, 1997 (vol 156, no 7) / JAMC le 1 avril 1997 (vol 156, no 7) |

/ >

Table 3: Estimated cost-effectiveness ratios for long-term (15-year) simvastatin treatment in Canada according to 3 premises of clinical benefit
		Cost per YLG ą 20%,‡ $
Premise*	Cost per YLG,† $	-20%	+20%
A (one-time benefit)	29 888	22 695	37 081
B (semicontinuous benefit)	9 867	7 044	12 690
C (continuous benefit)	6 108	4 030	8 186
*See Methods for descriptions of premises. †YLG = year of life gained. ‡Costs are varied by 20% for sensitivity analysis.